原著論文
2024
| ● | Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study. |
| Hata K, Nakamura K, Maeda S, Maeda M, Fujio Y, Hirobe S | |
| Clin. Pract. 14(2): 377-387 (2024) | |
2021
| ● | Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions. |
| Yokoyama H, Shioyama W, Shintani T, Maeda S, Hirobe S, Maeda M, Sakata Y, Fujio Y | |
| Int.Heart J. 62(6): 1297-1304 (2021) | |
| ● | 兵庫県養父市および福岡市の国家戦略特区におけるオンライン服薬指導実証事業実施に関するアンケート調査 |
| 犬飼萌乃, 横山俊之, 大門力男, 松浦伸史, 田中亮太, 廣部祥子 | |
| 医療薬学 47(2): 106-116 (2021) | |
2019
| ● | Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients. |
| Sasano M, Ohno M, Fukuda Y, Nonen S, Hirobe S, Maeda S, Miwa Y, Yokoyama J, Nakayama H, Miyagawa S, Sawa Y, Fujio Y, Maeda M | |
| Eur. J. Clin. Pharmacol. 1-11 (2019) | |
2018
| ● | Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. |
| Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y | |
| Oncotarget 9(101): 37520-37533 (2018) | |
2016
| ● | Four cases of investigational therapy with interleukin-11 against acute myocardial infarction. |
| Nakagawa M, Owada Y, Izumi Y, Nonin S, Sugioka K, Nakatani D, Iwata S, Mizutani K, Nishimura S, Ito A, Fujita S, Daimon T, Sawa Y, Asakura M, Maeda M, Fujio Y, Yoshiyama M | |
| Heart Vessels. 31(9): 1574-1578 (2016) | |
2015
| ● | Vascular Functional and Morphological Alterations in Smokers during Varenicline Therapy. |
| Kobayashi M, Takemoto Y, Norioka N, Iguchi T, Shimada K, Maeda M, Morimura M, Fujio Y, Azuma J, Yoshiyama M, Hirohashi K, Shuto T | |
| Osaka City Med. J. 61(1): 19-30 (2015) | |
